Below are the Southampton Clinical and Experimental Neurology Team's research studiesÌýrelated to brain haemorrhage.
Ìý
Non-visible deficits after subarachnoid haemorrhage
Many people with lived experience of subarachnoid haemorrhage cannot return to their previous level of functioning, despite looking outwardly well. This is due to a number of non-visible deficits which impact quality of life and productivity, such as , , and . Ongoing work is focusing on other such non-visible deficits.
Funded by the ÃÛÌÒTV.
Ìý
Haptoglobin as a treatment after subarachnoid haemorrhage
Haptoglobin is a natural protein which binds haemoglobin and can protect the brain from haemoglobin toxicity. We have demonstrated proof-of-concept that haptoglobin prevents the deleterious effect of haemoglobin in and in a . Further studies are ongoing to prepare for Phase I clinical trial.
Funded by the , Ìýand .
Ìý
Genome-wide association study (GWAS)Ìýof outcome after subarachnoid haemorrhage
ÃÛÌÒTVing the genetic determinants of clinical outcome after subarachnoid haemorrhage in order to identify novel therapeutic targets and improve current prognostic algorithms. This is an international study of the HATCH consortium, led from the ÃÛÌÒTV. A preliminary exploratory study using already available genotype data has shown , recruitment of cases continues and we are currently seeking funding to type 7,000 cases from the consortium.
Funded by the ÃÛÌÒTV, Ìýand .
Ìý
Proteomic and metabolomic correlates of outcome after subarachnoid haemorrhage
ÃÛÌÒTVing the biochemical signatures in blood and cerebrospinal fluid at protein and metabolite levels, correlating with outcome, with two aims: (1) discovery of therapeutic targets (2) prognostication.
Funded by the ÃÛÌÒTV,ÌýÌýand .
Ìý
Prevention of aneurysmal rupture
Subarachnoid haemorrhage is most often the result of rupture of a swelling on a cerebral artery called an aneurysm. Identifying modifiable risk factors for aneurysmal formation and rupture is key. Enhanced aneurysmal rupture prediction models would better inform the clinical need for surgery to remove the aneurysm. We are undertaking histological and imaging studies of ruptured and unruptured aneurysms to determine the underyling mechanisms leading to rupture.Ìý
Funded by the ÃÛÌÒTVÌýand theÌý.
Ìý
Haemoglobin scavenging kinetics in the brain after subarachnoid haemorrhage
Haemoglobin is neurotoxic once outside red blood cells. Treatments to improve haemoglobin clearance from the brain after haemorrhage may be possible. We are studying the kinetics of haemoglobin clearance to define the limits of the therapeutic window.
Funded by the .
Ìý
Sulphoradex After Subarachnoid haemorrhage (SAS) study
A randomized controlled study of a stable formulation of sulforaphane after subarachnoid haemorrhage (see and ).
Funded by .
Ìý
Haptoglobin genotype and long-term clinical outcome after aneurysmal subarachnoid haemorrhage
Haptoglobin exists in two forms which might differ in how this protein affects clinical outcome after subarachnoid haemorrhage. With over 1000 participants, this is the largest single study examining this issue.
Funded by the .
Ìý
Haptoglobin genotype and outcome after intracerebral haemorrhage
Haptoglobin exists in two forms which might differ in how this protein affects clinical outcome after intracerebral haemorrhage. Initial findings are published in the journal .
Funded by the .
Ìý
SubArachnoid Haemorrhage Outcome Tool (SAHOT)
Developing a clinical outcome tool specific for subarachnoid haemorrhage, published in . It is being translated into seven languages and current work is aiming to develop the tools to facilitate its clinical deployment.
Funded by the ÃÛÌÒTVÌýand theÌý.
Ìý
Hearing difficulty after subarachnoid haemorrhage
We have discovered that hearing loss affects a significant proportion of survivors after subarachnoid haemorrhage, and is characterized as a central auditory processing disorder. WeÌýhave worked out the of development of this hearing difficulty, have confirmed its relationship with in a , provided proof-of-concept that , and are currently planning a randomised controlled trial.
Funded by the ÃÛÌÒTV.
Ìý
A neuropathological study of the haemoglobin scavenging system after subarachnoid haemorrhage
To understand how haemoglobin is cleared from the brain, using post-mortem specimens from people after subarachnoid haemorrhage and control individuals. We have made seminal observations regarding the Ìýafter subarachnoid haemorrhage; further studies are ongoing.
Funded by the ÃÛÌÒTV.
Ìý
Haptoglobin genotype and outcome after subarachnoid haemorrhage
Haptoglobin exists in two forms which might differ in how this protein affects clinical outcome after subarachnoid haemorrhage. This is an international collaboration to enable an individual patient level data analysis of data in small published and unpublished studies, which has been . An update of a of published studies is ongoing.
Funded by the ÃÛÌÒTV.
Ìý
Haptoglobin genotype and outcome after sepsis
Haptoglobin exists in two forms which might differ in how this protein affects clinical outcome after sepsis.
Funded by the ÃÛÌÒTV.
Ìý
Ìý